Press "Enter" to skip to content

Bluebird prices gene therapy at 1.58 million euros over 5 years

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/JHOzwbx2rSg/bluebird-prices-gene-therapy-at-1-58-million-euros-over-5-years-idINKCN1TF1HP

Also Read:   FDA approves first biosimilar to Roche cancer drug Rituxan